In the BioHarmony Drug Report Database

"Preview" Icon

Tafasitamab

Monjuvi, Minjuvi (tafasitamab) is an antibody pharmaceutical. Tafasitamab was first approved as Monjuvi on 2020-07-31. It is used to treat large b-cell lymphoma diffuse in the USA. It has been approved in Europe to treat large b-cell lymphoma diffuse. The pharmaceutical is active against B-lymphocyte antigen CD19.

 

Trade Name

 

Minjuvi
 

Common Name

 

tafasitamab
 

ChEMBL ID

 

CHEMBL4298047
 

Indication

 

large b-cell lymphoma diffuse
 

Drug Class

 

Monoclonal antibodies: tumors

Image (chem structure or protein)

Tafasitamab structure rendering